<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107739</url>
  </required_header>
  <id_info>
    <org_study_id>NX-DeTIL-0255-201</org_study_id>
    <nct_id>NCT05107739</nct_id>
  </id_info>
  <brief_title>A Study of DeTIL-0255 in Adults With Advanced Malignancies</brief_title>
  <official_title>A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nurix Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nurix Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate&#xD;
      the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes a safety run in and a cohort expansion. The safety run in will include&#xD;
      patients with any of the indications under study including:&#xD;
&#xD;
      Recurrent or persistent platinum-resistant epithelial ovarian cancer (EOC), including primary&#xD;
      peritoneal and fallopian tube carcinoma Recurrent, metastatic, or persistent cervical&#xD;
      carcinoma Advanced or recurrent endometrial cancer&#xD;
&#xD;
      Cohort expansion will include patients with advanced malignancies who have received at least&#xD;
      two prior systemic therapies in the same indications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>24 Months</time_frame>
    <description>NX-DeTIL-0255-201</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of all deaths</measure>
    <time_frame>24 Months</time_frame>
    <description>NX-DeTIL-0255-201</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities</measure>
    <time_frame>24 Months</time_frame>
    <description>NX-DeTIL-0255-201</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) per disease-specific response criteria as assessed by the Investigator</measure>
    <time_frame>24 Months</time_frame>
    <description>NX-DeTIL-0255-201</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DOR) as assessed by the Investigator</measure>
    <time_frame>24 Months</time_frame>
    <description>NX-DeTIL-0255-201</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease control rate (DCR) as assessed by the Investigator</measure>
    <time_frame>24 Months</time_frame>
    <description>NX-DeTIL-0255-201</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) as assessed by the Investigator</measure>
    <time_frame>24 Months</time_frame>
    <description>NX-DeTIL-0255-201</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS) as assessed by the Investigator</measure>
    <time_frame>24 Months</time_frame>
    <description>NX-DeTIL-0255-201</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in immune cell infiltration in the tumor following DeTIL-0255 infusion</measure>
    <time_frame>24 Months</time_frame>
    <description>NX-DeTIL-0255-201</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Platinum-resistant Ovarian Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Safety Run In</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with gynecological malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent or persistent platinum-resistant epithelial ovarian cancer (EOC), including primary peritoneal and fallopian tube carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent, metastatic, or persistent cervical carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced or recurrent endometrial cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Drug Product De-TIL-0255</intervention_name>
    <description>Autologous tumor-infiltrating lymphocytes</description>
    <arm_group_label>Cervical</arm_group_label>
    <arm_group_label>EOC</arm_group_label>
    <arm_group_label>Endometrial</arm_group_label>
    <arm_group_label>Safety Run In</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  One of the following malignancies: Recurrent or persistent platinum-resistant EOC,&#xD;
             recurrent, metastatic or persistent carcinoma of the cervix with progression after&#xD;
             treatment with taxane-containing regimen, or advance or recurrent endometrial cancer&#xD;
             with disease progression after or during second line or greater therapy&#xD;
&#xD;
          -  Disease that is metastatic and measurable by RECIST v1.1 criteria&#xD;
&#xD;
          -  A resectable lesion for TIL generation&#xD;
&#xD;
          -  At least 2 prior lines of therapy&#xD;
&#xD;
          -  ≥ 18 years and ≤ 70 years of age&#xD;
&#xD;
          -  Life expectancy of at least 4 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Adequate organ and bone marrow function, in the absence of growth factors&#xD;
&#xD;
          -  Patients of child-bearing potential must use adequate contraceptive measures to avoid&#xD;
             pregnancy for the duration of the study as defined in the protocol&#xD;
&#xD;
          -  A signed consent form indicating that the subjects understands the purpose and&#xD;
             procedures required for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known untreated brain metastases&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  History of known seizure disorder&#xD;
&#xD;
          -  Unable to comply with study requirements&#xD;
&#xD;
          -  Toxicities from previous anticancer therapies that have not resolved to baseline&#xD;
             levels or to Grade 1 or less except for alopecia and peripheral neuropathy&#xD;
&#xD;
          -  Pregnant, breastfeeding, or planning to become pregnant while enrolled on this study&#xD;
             or within 6 months after DeTIL infusion&#xD;
&#xD;
          -  Live vaccine within 28 days of first dose of NMA chemotherapy or planned live&#xD;
             vaccination within 6 months following DeTIL infusion&#xD;
&#xD;
          -  Active known second malignancy with the exception of any of the following: Adequately&#xD;
             treated basal cell carcinoma, squamous cell carcinoma of the skin, or adequately&#xD;
             treated follicular or papillary thyroid cancer; or any other cancer from which the&#xD;
             patient has been disease-free for ≥ 2 years&#xD;
&#xD;
          -  Systemic anti-cancer therapy, including investigational agents, or radiotherapy within&#xD;
             4 weeks of tumor resection&#xD;
&#xD;
          -  Major surgery within 4 weeks before tumor resection, or will not have fully recovered&#xD;
             from surgery, or has surgery planned within 8 weeks after infusion&#xD;
&#xD;
          -  Use of systemic corticosteroids within 15 days (or other immunosuppressive drugs&#xD;
             within 30 days) prior to tumor resection&#xD;
&#xD;
          -  Use of biotin or other supplements containing higher that the daily adequate intake of&#xD;
             biotin&#xD;
&#xD;
          -  Clinically significant, uncontrolled cardiac, class III or IV heart failure,&#xD;
             thromboembolic events, cardiovascular disease, or history of myocardial infarction&#xD;
             within 6 months of planned start of study drug&#xD;
&#xD;
          -  History or current evidence of anything that might confound the results of the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Brown</last_name>
    <role>Study Director</role>
    <affiliation>Nurix Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NX0255-201 Patient Outreach</last_name>
    <phone>415-417-3418</phone>
    <email>nx0255201@nurixtx.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NX-DeTIL-0255</keyword>
  <keyword>Adoptive Cell Therapy</keyword>
  <keyword>Tumor Infiltrating Lymphocyte</keyword>
  <keyword>ACT</keyword>
  <keyword>TIL</keyword>
  <keyword>DeTIL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

